Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL93807 | 0.94 | DNMT1 (0.37) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL8482977 | 0.94 | DNMT1 (0.37) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL207077 | 0.93 | DNMT1 (0.36) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL9125279 | 0.93 | DNMT1 (0.36) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL8058737 | 0.91 | MAPT (0.35) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL626502 | 0.91 | DNMT1 (0.35) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL6259658 | 0.88 | MAPT (0.41) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL17609997 | 0.87 | MAPT (0.37) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL16684529 | 0.87 | MAPT (0.40) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL8429242 | 0.85 | MAPT (0.36) | MAPTHTTTP53STAT3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021067604-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | DREXEL UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-1675824-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | Oy Juvantia Pharma Ltd (FI) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005033069-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |